24 C
Port Moresby
February 27, 2021
International Pacific

Australia’s Starpharma, Ansell to supply anti-Zika condoms for Olympics

Share the News

Image: An edes aegypti mosquito is seen inside a test tube as part of a research on preventing the spread of the Zika virus and other mosquito-borne diseases at a control and prevention center in Guadalupe, neighbouring Monterrey, Mexico, March 8, 2016. REUTERS/Daniel Becerril/File Photo

 

SYDNEY (Reuters) – Australian pharmaceutical company Starpharma Holdings Ltd said it is teaming up with world No. 2 condom maker Ansell Ltd to supply Zika virus-proof condoms to the Australian Olympic team ahead of the 2016 Rio de Janeiro games.

Starpharma said it is giving the Australian athletes Ansell “Dual Protect” condoms lubricated with Starpharma’s VivaGel product, which it recently said showed near-total antiviral protection against Zika and other viruses in laboratory studies.

“Given sexual transmission of Zika virus is of increasing importance, the potent activity of Starpharma’s VivaGel against Zika could prove very significant,” said Starpharma Chief Executive Officer Jackie Fairley in a statement.

The Australian Olympic Committee (AOC) said the Starpharma condoms would be in addition to condoms already shipped to the Olympic village, which will also have free dispensing machines on every block supplying 350,000 male condoms and 100,000 female condoms to athletes.

The AOC dismissed suggestions that athletes returning from Rio should undergo compulsory blood testing. People who follow the recommended precautions have a low risk of Zika and blanket testing “is not aligned with medical or scientific best practice,” it said in a statement.

(Reporting by Byron Kaye; Editing by Richard Pullin)

Copyright 2016 Thomson Reuters. Click for Restrictions.

Related posts

Krakatau-triggered tsunami kills at least 168 in Indonesia – media

Reuters

Gazans use home-made masks against Israeli tear gas

Reuters

Italy’s mayoral elections deal defeat to Renzi; 5-Star breakthrough

Reuters
error: Content is protected !!